Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Silverman

Pediatric Dermatology Fairfax, VA Medical Doctor

NPI 1881694651 CMS profile 130204

8316 Arlington Blvd, Ste 524, Fairfax, VA 22031

Open in the dashboard

General payments

$34,444

348 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Silverman of Fairfax, VA is reported in the CMS Open Payments database as having received $34,444 across 348 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pediatric Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $537 5
2024 General $1,912 74
2023 General $1,734 73
2022 General $1,322 43
2021 General $1,794 12
2020 General $9,023 53
2019 General $18,122 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Silverman
  • Pediatric Dermatology median
  • Middle half of Pediatric Dermatology
  • National median

In program year 2025, general payments to Robert Silverman were reported at $537. Among 172 Pediatric Dermatology profiles paid that year, the median was $302 and the middle half received between $110 and $2,128.

Show as a table
Year Robert Silverman Pediatric Dermatology median Middle half National median
2019 $18,122 $280 $89–$1,853 $163
2020 $9,023 $263 $71–$2,376 $114
2021 $1,794 $227 $69–$1,800 $132
2022 $1,322 $289 $69–$1,516 $149
2023 $1,734 $537 $114–$3,255 $160
2024 $1,912 $437 $114–$2,693 $164
2025 $537 $302 $110–$2,128 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $12,267 50 payments
  2. Genzyme Corporation $8,506 19 payments
  3. Pfizer Inc. $6,697 61 payments
  4. AbbVie, Inc. $1,297 32 payments
  5. Janssen Biotech, Inc. $1,061 43 payments
  6. Incyte Corporation $576 17 payments
  7. Almirall LLC $472 5 payments
  8. Lilly USA, LLC $328 15 payments
  9. LEO Pharma Inc. $325 13 payments
  10. Galderma Laboratories, L.P. $276 11 payments
  11. Other $2,639 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,644 10 payments
  2. Food and Beverage $9,222 330 payments
  3. Consulting Fee $2,918 3 payments
  4. Travel and Lodging $1,480 3 payments
  5. Education $179 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $12,306 52 payments
  2. EUCRISA $5,653 55 payments
  3. DUPIXENT Immunology $5,509 19 payments
  4. DUPIXENT Immunology $3,076 3 payments
  5. TREMFYA $1,055 38 payments
  6. SKYRIZI $778 21 payments
  7. OPZELURA $576 17 payments
  8. Seysara $451 4 payments
  9. LITFULO $423 20 payments
  10. HUMIRA $395 9 payments
  11. Other $4,991 204 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$14,981

Medicare's payments for the services billed

Medicare patients

73

Average age 78

Services billed

295

27 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 49%
Ischemic heart disease 26%
Osteoporosis 23%
Chronic kidney disease 18%
Diabetes 15%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $399
$399 — —
DUPIXENT
  • GENZYME CORPORATION $196
  • Regeneron Healthcare Solutions, Inc. $49
  • Regeneron Pharmaceuticals, Inc. $18
$263 — —
OPZELURA
  • Incyte Corporation $193
$193 — —
VTAMA
  • Dermavant Sciences, Inc. $104
$104 — —
YCANTH
  • VERRICA PHARMACEUTICALS INC. $101
$101 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Dermatology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record